Abstract Atherosclerosis imaging strategies can delineate characteristics of plaques at risk of rupture and thrombosis. Structural plaque imaging identifies high-risk plaque features, including lipid pools, thin fibrous caps, and intraplaque hemorrhage. New molecular imaging techniques complement structural imaging approaches by illuminating important features of plaque biology, with a prominent focus on detecting inflammation as a high-risk phenotype. As we unravel the molecular and structural characteristics underlying thrombosis-prone plaques, there is significant promise for eventual early identification and prediction of atherosclerotic plaque complications before they occur. Here we focus on recent imaging insights into highrisk arterial plaques, the etiologic agent of acute myocardial infarction, stroke, and sudden cardiac death.
Introduction
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality worldwide. Plaque complications occur most commonly from plaque rupture, and also from plaque erosion and calcified nodule formation. In the last several years, advanced structural and molecular imaging technologies have emerged and offer new windows into atherosclerosis pathophysiology. Recently, an expert working group summarized the current knowledge base for high-risk plaque (HRP) imaging, and provided directions for future research [1] . Although it is recognized that atherosclerosis is a systemic disease requiring systemic treatment [2] , myocardial infarction (MI), stroke, and death occur from specific lesion complications, offering a sound rationale for precomplication imaging. The development and clinical translation of structural and molecular plaque imaging approaches will refine our ability to identify HRP, with important implications for risk prediction, drug development, and personalized medicine.
Extensive postmortem histopathological studies of coronary and carotid plaques have identified key features of HRP (aka "vulnerable" plaques), including (1) a thin fibrous cap, (2) a lipid-rich necrotic core, (3) inflammation, (4) neovascularization, (5) intraplaque hemorrhage (IPH), (6) microcalcifications, and potentially (7) cholesterol crystals. Plaques with thin fibrous caps and large thrombogenic lipid cores, known as thin-cap fibroatheromas (TCFAs), are the prototypical substrate for plaque rupture and atherothrombosis. Inflammation due to macrophage infiltration and destabilizing activated tissue proteases can weaken the fibrous cap. Hemorrhage into the plaque itself has been implicated in progression to more advanced lesions. Finally, small calcified nodules may induce plaque disruption caused by local mechanical stress on softer adjacent tissue structures. These features may be present alone or in combination in a particular HRP, and can evolve as the plaque matures into a more vulnerable phenotype or stabilizes in response to effective treatment. Importantly, many high-risk features are increasingly detectable by clinical structural and molecular imaging tools.
A recent invasive and noninvasive imaging autopsy study of 295 coronary atherosclerotic plaques obtained from 213 sudden cardiac death patients identified cap thickness of less than 55 μm as the best concomitant discriminator of plaque rupture, followed by inflammation (macrophage infiltration) and a necrotic core [3••] . Although highly informative, histopathological investigations are limited by single time point, cross-sectional associations. In vivo imaging studies that visualize the structure and biology of HRP ahead of plaque disruption are critically needed to understand its complex and dynamic pathophysiology, such as serial rupture, inflammation, regression, and erosion.
Structural Plaque Imaging
Multidetector CT Coronary Angiography Multidetector CT coronary angiography (MDCTA) has emerged as the leading platform for noninvasive coronary plaque imaging owing to its high speed and resolution. Current-generation 320-slice MDCTA systems can image the entire heart with a single gantry rotation in seconds at submillimeter resolution. MDCTA can detect both lumen stenosis (sensitivity and specificity greater than 90 % compared with invasive imaging), and plaque composition based on tissue density measured in Hounsfield units (HU), potentially discriminating high-attenuation calcification from low-HU fibrofatty plaques.
MDCTA Plaque Composition and Cardiovascular Events
Nance et al. [4] studied 458 subjects at low-to-intermediate cardiac risk seeking acute care for chest pain who underwent coronary MDCTA and then were followed for major adverse cardiovascular events (MACE), including MI, revascularization, cardiac death, or angina requiring hospitalization. Overall, 15 % of patients experienced MACE at 13 months' median follow-up, with plaque extent independently strongly predicting MACE [hazard ratio (HR) of 152 for four segments of plaque compared with no plaque, p <0.001]. MACE rates were highest in fibrofatty and mixed calcified plaques (HR 87), followed by purely noncalcified (HR 58) and calcified (HR 33) lesions (all p <0.05).
Nonobstructive Coronary Artery Disease and Acute MI
Aldrovandi et al. [5• ] revealed a new association of nonobstructive coronary atherosclerosis (less than 50 % stenosis) and subjects with acute MI, a difficult clinical scenario including a differential diagnosis of myocarditis, coronary vasospasm, and plaque disruption with thromboemboli. They performed MDCTA in 50 MI patients with nonobstructive CAD on invasive coronary angiography (ICA), but MI evidenced by MRI late-gadolinium enhancement. First, they noted that MDCTA identified many plaques not visible on ICA. Of MDCTA-detected plaques, 60 % were located in the infarct-related artery, and these plaques exhibited significantly more noncalcified and mixed calcified/fibrofatty composition than non-infarct-related-artery plaques (64 % vs 32 %, p = 0.005). These results suggest that nonobstructive CAD could be the etiological cause of many acute MIs, warranting greater secondary prevention therapies. Further insights are expected in this very important patient subgroup using intravascular imaging.
Magnetic Resonance Imaging
The advantages of MRI include excellent inherent soft-tissue contrast, good resolution, and no ionizing radiation exposure. In the carotid arteries, multi-contrast-weighted MRI readily detects lipid-rich necrotic core plaques, plaque erosion and rupture, and IPH, in addition to determining the percentage of luminal stenosis. Serial plaque MRI has emerged as an imaging end point in outcome and drug development clinical trials.
MRI Plaque Composition and Cardiovascular Risk Factors
The association of cardiovascular risk factors and MRI carotid plaque composition was evaluated in 1,006 subjects with intimal thickening on carotid ultrasonography [6] . Carotid MRI revealed that IPH and lipid core were the commonest findings, and occurred in 25 % of all subjects, but more often in men. On multivariate analysis, IPH was associated with age, smoking, and hypertension [odds ratio (OR) of 1.8, 1.6, and 1.4, respectively], whereas lipid cores were commoner in only hypercholesterolemic patients (OR 1.4). Since the high frequency of HRP features observed would be expected to far outpace the number of clinical events, this study highlights the need to develop combinatorial risk scores for individual plaque risk, and of course prospective studies to validate such criteria.
Associations Between Cryptogenic Stroke and Complicated, Nonobstructive Plaques
Analogous to the coronary arteries, the link between nonobstructive carotid plaques and stroke is incompletely understood. In 32 patients with nonobstructive carotid stenosis of less than 50 % and cryptogenic stroke [7] , complicated HRP (MRI-identified American Heart Association type VI lesions with thrombus, fibrous cap rupture, and/or IPH) were found in 37.5 % of carotid arteries ipsilateral to the stroke, in contrast to 0 % in the contralateral carotid artery (p =0.001). In a second study, 41 patients with transient ischemic attack (TIA) or stroke demonstrated a 54 % rate of MRI-defined complex American Heart Association type VI lesions in the ipsilateral culprit vessel, also with IPH as the predominant feature. Remarkably, over half of these lesions were less than 70 % stenosed [8] . These data strengthen the concept that severe stenosis is not a prerequisite for carotid-plaqueinduced thromboembolism and subsequent stroke or TIA.
IPH and Plaque Progression
IPH may predict rapid carotid plaque progression. Sun et al. [9] serially imaged 12 asymptomatic patients with 50-79 % stenosed carotid arteries over 4.5 years. Each patient developed IPH in at least one carotid artery. Plaque progression was initially low (−20.5 ± 13.1 mm 3 /year), but then rapidly accelerated after IPH appeared (18.3 ± 6.5 mm 3 /year, p <0.02). Despite enhanced plaque progression, no cerebral ischemic events occurred in this small study. However, a larger investigation of 114 symptomatic carotid stenosis patients reported that IPH was strongly associated with stroke or TIA (OR 4.1) [10] . In addition, IPH predicted ischemic events (OR 6.7 for new symptoms within 2 weeks). Thus, MRI-detected IPH indicates evolving plaque risk, and may ultimately help reclassify patients.
Intravascular Ultrasonography
A widely used invasive imaging tool, intravascular ultrasonography (IVUS) has been a pillar of clinical structural plaque imaging technology for many years. IVUS uses miniaturized ultrasound transducers to obtain images of the vessel wall at up to 100-μm resolution, and can determine not only lumen stenosis as observed by angiography, but also the positive expansive vessel remodeling that occurs in earlierstage plaques before luminal narrowing. Clinically, IVUS is used to guide coronary intervention, resolve ambiguous left main coronary artery lesions, and evaluate atherosclerotic lesion length and plaque burden.
Grayscale IVUS Calcified Nodules and Plaque Progression
Plaque progression is linked to focal plaque calcification, an HRP feature readily identified by grayscale IVUS. Kataoka et al. [11] performed serial IVUS on 1,374 patients with stable CAD. Plaques from 922 patients contained spotty calcification, defined as an arc of calcified plaque that encompasses less than 90°of the IVUS cross-sectional image. Spotty calcification existed in older, male, and diabetic subjects. Over time, plaques exhibiting spotty calcification progressed at rates 20-fold greater (measured as an increase in the percent atheroma volume, p =0.002). Of concern, plaque growth was more resistant to intensive cholesterol and blood pressure control when spotty calcifications were present.
Virtual Histology IVUS Plaque Composition
Although grayscale IVUS can effectively differentiate calcified (bright, high-density reflectors) from noncalcified plaque, it has limited capacity to determine the composition of noncalcified plaque tissue. However, spectral analysis of the IVUS backscatter signal has given rise to virtual histology (VH) IVUS, which can reasonably identify four distinct plaque components: calcified, fibrous, fibrofatty, and necrotic core. VH IVUS can further differentiate plaques into TCFAs and thick-cap fibroatheromas, fibrocalcific plaques, and pathological intimal thickening. Recent evidence demonstrates that human coronary and peripheral atheroma show marked heterogeneity in VH plaque composition, with coronary and carotid arteries harboring more HRP phenotypes than the renal and iliac arteries [12] . Comprehensive definitions for grayscale IVUS and VH IVUS plaque analysis have been published to standardize interpretation for future clinical studies [13] .
VH IVUS and Prediction of Coronary Events

VH IVUS was used in the recent landmark Providing Regional Observations to Study Predictors of Events in the Coronary
Tree (PROSPECT) trial. The PROSPECT trial evaluated the natural history of all 30 % or greater stenosed coronary plaques identified by ICA and three-vessel grayscale IVUS and VH IVUS in 697 ACS patients [14••] . At more than 3 years' follow-up, half of new cardiovascular events were attributable to plaques distinct from the index culprit lesion. The adverse event rate related to IVUS was nontrivial at 1.6 % (ten dissections, one perforation). Independent predictors of future nonculprit plaque adverse events included plaque burden greater than 70 %, minimum lumen area less than 4 mm 2 , and VH TCFA (defined as a necrotic core that extends to the lumen surface). These plaque features were additive in their risk, and in combination predicted an 18 % likelihood of MACE at 3 years compared with 0.3 % in nonculprit plaques without these features. However, the predictive accuracy of VH IVUS is currently too low for routine clinical risk prediction.
Subgroup analyses of the PROSPECT trial have yielded further interesting findings. Two hundred and twenty-two patients with at least one lesion with a plaque burden greater than 70 % had overall greater residual atherosclerotic disease with more VH IVUS necrotic core and TCFAs [15] . This population had significantly higher numbers of nonculprit lesion MACE compared to those without lesions with a plaque burden greater than 70 % (20.8 % vs 7.7 %, p <0.0001), supporting the concept that greater residual coronary disease is associated with greater future risk. Significant lesion progression was also evaluated as a marker of future adverse events in the 72 patients who experienced nonculprit lesion events in the PROSPECT trial [16] . Despite similar baseline IVUS metrics, the 44 patients with evidence of lesion progression of 20 % or more by ICA at the time of their event accounted for all of the six MIs observed in the 3-year study period. In contrast, the events in patients without significant lesion progression were solely unstable angina without MI. Therefore, understanding individual plaque characteristics that predispose to lesion growth and maturation may be most important to prevent infarction. Although in the PROSPECT trial lesion palpography did not provide further discrimination of future MACE [17] , a separate study demonstrated that low local endothelial shear stress in combination with larger IVUS plaque burden independently predicted plaque progression [18] .
Optical Coherence Tomography
Intravascular optical coherence tomography (OCT), and the high-speed second-generation form termed "optical frequency domain imaging" (OFDI) uses reflected near-infrared light to obtain unsurpassed high-resolution (approximately 10-μm) images of the vessel wall. OCT requires a blood-free imaging field through brisk saline or contrast medium flushing for image visualization. OFDI acquires data rapidly at rates up to 40 mm/s. OCT/OFDI can evaluate intravascular thrombus, macrophage infiltration, and subintimal lipid accumulation, and can even image the thin fibrous caps of TCFAs that are unresolvable by IVUS. OCT outperforms MDCTA and IVUS in discriminating early from advanced lesions in donor heart coronary arteries, where lipid-rich OCT plaques significantly predicted advanced atheroma on histopathology (OR 31.2, p <0.0001) [19] . Consensus standards for OCT acquisition and measurement have recently been formulated by an international working group [20] .
OCT Plaque Composition, Positive Remodeling, and the Influence of Diabetes
Positively remodeled or expansive atherosclerotic plaques are implicated as having a higher risk of plaque rupture. Rathore et al. [21] used OCT and IVUS in 47 patients to assess the relationships between plaque remodeling and structural features. Positively remodeled plaques exhibited greater lipid content, thinner fibrous caps, and more TCFAs, thrombus, and sites of plaque rupture. In 98 patients with diabetes, OCT plaque analysis demonstrated greater plaque lipid content, calcification, and thrombus compared with nondiabetic subjects [22] , consistent with the recognition that diabetic subjects have more complex and diffuse coronary disease. When stratified further by blood glucose levels, poorly controlled diabetic subjects (hemoglobin A 1c level of 8.0 % or greater) had even greater plaque lipid content and thinner fibrous caps (p <0.02 for both trends), with more TCFAs and plaque macrophage infiltration.
OCT and VH IVUS Plaque Composition as Measures of Statin Efficacy
In a prospective study of 42 patients with coronary revascularization for stable angina and then randomized to receive 4 mg pitavastatin daily or dietary changes, serial OCT, grayscale IVUS, and VH IVUS were performed at the baseline and at 9 months' follow-up [23] . In the statin-treated group, grayscale IVUS plaque volume and VH IVUS lipid volume index both significantly decreased at 9 months, in contrast to the dietary change group (p <0.05). By OCT, plaque fibrous cap thickness was also greater after statin therapy (189 ± 46 μm vs 140 ± 42 μm, p =0.001). These results demonstrate the effects of statin treatment on HRP characteristics, and the potential of using advanced plaque imaging to provide surrogate coronary efficacy biomarkers for novel atherosclerosis therapeutics.
OCT Plaque Analysis in Acute Coronary Syndromes Versus Stable CAD
Three-vessel OCT was used to assess 248 nonculprit plaques in 17 ACS patients and 87 stable CAD patients [24] . Compared with plaques from stable CAD patients, plaques from ACS patients demonstrated greater lipid accumulation, thinner fibrous caps, and more TCFAs (65 % vs 15 %, p <0.001), as well as more macrophages and greater thrombus content. Nonculprit lesion neovascular microchannels were detected at similar frequency in the two groups, but they could be observed significantly closer to the vessel lumen in ACS patients, which in theory could make these plaques more susceptible to disruption.
In ST-elevation MI, OCT is providing new insights into the mechanisms of atherothrombosis, and informing new management strategies. Prati et al. [25• ] studied 31 ST-elevation MI patients with OCT-defined plaque erosion (identified as a nonruptured fibrous cap following aspiration thrombectomy) who were treated with coronary stents (40 %) or dualantiplatelet therapy alone. Multimodality imaging was performed in a subset of patients, demonstrating different HRP imaging strategies (Fig. 1) . At 2 years' follow-up, no MI or death occurred in either group, and only a single targetvessel revascularization was performed, notably in the group treated with stents. Distinguishing plaque erosion from plaque rupture by OCT in ACS patients could spare erosion patients the infrequent, but important, risks of stent implantation such as restenosis and stent thrombosis.
Near-Infrared Spectroscopy
Near-infrared spectroscopy (NIRS) is a new clinical intravascular imaging modality that detects lipid-rich plaques on the basis of the pattern of the absorption of near-infrared light by cholesterol moieties. Since NIRS provides minimal anatomic Fig. 1 Acute coronary syndrome multimodality plaque imaging in a 66-year-old man with ST-elevation MI and an intact fibrous cap as determined by optical coherence tomography (OCT). a The patient presented with intermittent substernal chest discomfort over a period of 12 h and anterior ST elevations on the electrocardiogram. Angiography demonstrated complete occlusion of the proximal left anterior descending coronary artery. The patient was given heparin and half-dose thrombolytics intravenously prior to transfer to a tertiary care center. b On arrival, further angiography revealed the left anterior descending coronary artery to be widely patent without residual thrombus or obstructive stenosis by OCT (arrows identify locations of OCT cross-sectional images). c Thrombus (red) was observed by coronary angioscopy (left top panel and left middle panel), but OCT demonstrated plaque with an intact fibrous cap (right top panel and right middle panel) consistent with plaque erosion as the cause of coronary thrombosis. Grayscale and virtual histology intravascular ultrasonography revealed mainly fibrous plaque (green) with scant fibrofatty tissue (blue) infiltrating the lesion (bottom panels). Ultimately, percutaneous intervention was deferred and the patient was treated with dual-antiplatelet therapy alone. d Before discharge, multidetector CT coronary angiography was performed (comparative reference angiography images on the left ) and showed nonobstructive coronary disease and no positive/expansive plaque remodeling at the site of the thrombotic culprit lesion. (Reproduced with permission from [25•]) information, it has been coupled with IVUS to display coregistered structural plaque data. Following automated catheter pullback, the NIRS data are displayed on a color-coded scale in blocks that range from red (no lipid) to yellow (lipidrich). NIRS has been extensively validated against histopathology in detailed human coronary studies, and its uses in patient care are still under active investigation.
A recent longitudinal preclinical study examining the evolution of at-risk coronary fibroatheromas in diabetic, hypercholesterolemic pigs tested whether early NIRS-IVUS plaque features could predict the development of future lipid-rich vulnerable plaques [26] . NIRS-IVUS was performed every 3 months for 9 months, and demonstrated progressive IVUS atherosclerosis and positive remodeling. Lipid-rich NIRS lesions were more likely to have multiple HRP histopathology features, including more necrotic core and inflammatory cells, and thinner fibrous caps with evidence of apoptosis (all p < 0.05). In total, nearly 90 % of 3-and 6-month NIRS-positive lesions evolved into histopathological fibroatheromas at 9 months (p <0.01), and furthermore the presence of an NIRS lipid-rich plaque at 6 months was predictive of this development (OR 2.7). The concept of using imaging tools to predict which early lesions will evolve into HRP is of importance.
Molecular Imaging
Molecular imaging complements traditional structural plaque imaging through the use of targeted probes that identify specific molecules and/or biological processes in vivo. Preclinical atherosclerosis molecular imaging has successfully identified nearly all established HRP features, including inflammation, thrombosis, neovessel formation, apoptosis, and hemorrhage, but clinical translation of molecular imaging has been slow compared with the rapid growth within the field. Recently, an expert panel commented on barriers and recommendations to foster greater clinical application of molecular imaging technologies [27] . Currently, clinical atherosclerosis molecular imaging is dominated by noninvasive PET metabolism/ inflammation plaque imaging with 18 F-fluorodeoxyglucose (FDG), but other clinically available approaches such as sodium 18 F-fluoride (NaF) for PET are emerging.
FDG Positron Emission Tomography
FDG is a radiolabeled glucose analogue that concentrates in metabolically active cells, including atheroma, where it associates with macrophage infiltration as a surrogate for plaque inflammation or possibly plaque hypoxia. FDG PET inflammation imaging is generally restricted to large arteries, such as the carotids and aorta, although coronary artery imaging is being pursued. FDG PET has high sensitivity but low spatial resolution (3 mm), and therefore requires anatomic imaging to localize the FDG signal. Traditionally, FDG PET is performed with CT; however, PET co-registered MRI is now available, offering greater plaque contrast and reduced radiation exposure [28] .
Carotid Plaque FDG Signal and Cardiovascular Risk Factors
In a recent study, FDG PET of 43 non-insulin-dependent diabetic subjects revealed a significant association between the corrected fasting glucose level and carotid FDG uptake [29] . Among this diabetic group, FDG signal was greatest in patients with obesity (BMI ≥ 30 kg/m 2 ) and who smoked. In a separate study of 21 peripheral arterial disease patients, however, there was no significant correlation between FDG PET activity and the macrophage content from catheter-based directional atherectomy plaque samples [30] . Although it is expected that FDG PET may provide different information in different atherosclerosis beds, a clear limitation of this study is the method of histopathology tissue collection, which makes exact co-registration problematic.
High-Risk Carotid Plaque Morphology and FDG Activity
Carotid FDG PET activity has been associated with early recurrent cerebral events regardless of stenosis severity, such as reported in a study of 60 patients with recent stroke or TIA [31••] . At 90 days, 22 % of subjects experienced recurrent events, with elevated ipsilateral carotid FDG signal being the only independent predictor identified (HR 6.1, p =0.02). Combining structural HRP with MDCTA may allow even greater risk stratification of high-risk carotid plaques, as investigated by FDG PET/CT in 34 patients with carotid stenosis [32] . Positively remodeled, ulcerated, and noncalcified plaques had significantly greater FDG PET signal [target-tobackground ratio (TBR) 2.2 vs 1.7, p <0.001], with incremental increases in FDG activity for each high-risk component (trend p <0.001). Risk stratification based on combined structural and molecular imaging appears to be a sound strategy.
Coronary Plaque FDG PET
Coronary FDG PET is challenging, in part owing to the small size of coronary vessels and cardiac motion artifacts, but also because of the intense FDG uptake of the adjacent highly metabolic myocardium that obscures the coronary FDG signal. However, with dietary myocardial suppression protocols, detection of FDG PET signal in the left main and proximal coronary artery beds is sometimes achievable. Noninvasive coronary FDG PET activity was investigated in the stented culprit lesions of 20 ACS subjects versus seven non-ACS subjects within 1 week of stent placement [33] . With use of a predetermined FDG TBR of 2.0 or greater to identify FDGpositive lesions, ACS correlated positively with elevated stent FDG signal (OR 31.6, p =0.044). However, coronary FDG signal was interpretable in only half of ACS patients, signifying the need for further improvements in coronary FDG PET.
Assessment of Anti-Inflammatory Pharmacotherapy by FDG PET Activity
Beyond statins, new antiatherosclerosis therapies are being pursued, including anti-inflammatory agents hypothesized to stabilize vulnerable plaques. Ongoing clinical trials of the interleukin-1β inhibitor canakinumab (Canukinamab Antiinflammatory Thrombosis Outcomes Study, CANTOS) and low-dose methotrexate (Cardiovascular Inflammation Reduction Trial, CIRT) aim to explore whether inflammation reduction leads to fewer adverse cardiovascular events. New antiinflammatory therapeutics are being tested by FDG PET, such as losmapimod, an inhibitor of the proinflammatory p38 mitogen-activated protein kinase pathway, and adalimumab, a TNF-α antagonist. Ninety-nine stable statin-treated patients randomized to received losmapimod or placebo demonstrated significant FDG signal reduction after receiving losmapimod for 3 months [34] . Subcutaneously administered adalimumab significantly decreased the maximum vessel TBR on serial FDG PET in 30 randomized patients at 4 months, but failed to reach significance compared with placebo owing to the small size [35] . FDG PET is likely to play an increasingly important role in the evaluation of pharmacotherapeutics in phase II clinical trials, to determine if more costly phase III trials should be pursued.
Non-FDG Nuclear Molecular Imaging Strategies
NaF PET of Coronary Calcification
Plaque calcification is a hallmark of advanced atheroma that can be detected with noninvasive NaF PET, a marker of active mineralization established clinically to detect cancer bone metastases. As opposed to FDG, background myocardial uptake of NaF is negligible, and therefore NaF can determine coronary osteogenic activity. A study of 119 patients revealed good correlation between coronary NaF and CT calcium scores (r = 0.652, p <0.001) [36•] . NaF signal was greatest in subjects with atherosclerosis risk factors, angina, and prior cardiovascular events, but undetectable in patients with the highest CT coronary calcium scores (greater than 1,000), presumably due to end-stage plaques lacking active calcium remodeling. Whether NaF activity can be reduced by medical therapy and its relationship to adverse outcomes are under investigation.
Newer Imaging Methods for Detecting Carotid Plaque Inflammation
Apart from FDG, agents targeted to inflammatory leukocyte subpopulations are also being tested in humans. 11 
C-PK11195
PET, which identifies activated plaque macrophages by selective engagement of the macrophage translocator protein, exhibited greatest uptake in the ipsilateral carotid artery after recent stroke or TIA in 32 patients with more than 50 % carotid stenosis [37] . When combined with high 11 C-PK11195 signal, lesions also demonstrating low attenuation on CT suggestive of greater lipid content were more than 90 % predictive of symptomatic carotid plaques. Although less abundant than macrophages, T lymphocytes are also present in HRP and can be detected by surface interleukin-2 (IL-2) receptors with the selective single photon emission scintigraphy agent 99m Tc-HYNIC-IL-2. A small study of 28 end-stage renal disease patients revealed elevated 99m Tc-HYNIC-IL-2 signals in 91 % of subjects [38] . Further assessment of different leukocyte subpopulations in plaques will provide new insights into the evolution of plaque inflammation.
Intravascular Near-Infrared Fluorescence Imaging
Standalone and Integrated Near-Infrared Fluorescence Imaging-OFDI Molecular Imaging Optical molecular imaging with near-infrared fluorescence (NIRF) catheters produces high-resolution intravascular images with good sensitivity, making NIRF imaging attractive for intracoronary molecular imaging. An informative inflammation study by Jaffer et al. [39] performed intravascular NIRF imaging in hypercholesterolemic rabbit aortas 24 h after injection of Prosense VM110, a protease-activatable NIRF inflammation agent. NIRF was detected through flowing blood, without vessel flushing or occlusion, demonstrating elevated NIRF in IVUS-verified atheroma. A separate study tested a new integrated NIRF-OFDI catheter capable of exact molecular-structural imaging in rabbit models of thrombosis and atherosclerosis inflammation [40] . The NIRF-OFDI catheter system demonstrated excellent performance, with nanomolar NIRF sensitivity and ultrahigh OFDI resolution (7 μm axially), and has a high probability of clinical translation in the next few years.
NIRF Imaging of Inflamed, Lipid-Rich Plaques
In addition to NIRF devices, clinical NIRF molecular imaging probes are needed. Indocyanine green (ICG), an FDAapproved NIRF retinal angiography agent, was recently demonstrated to target lipid-laden, inflamed lesions in atherosclerotic rabbits within 20 min of intravenous injection [41•] . ICG localized to macrophages ex vivo, and accumulated within human carotid endarterectomy samples after incubation. In parallel with approval of the NIRF-OFDI intravascular imaging system, ICG may be a leading NIRF coronary molecular imaging agent to identify biologically HRP.
